These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33955229)

  • 21. Assessment of Risk of Harm Associated With Intensive Blood Pressure Management Among Patients With Hypertension Who Smoke: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial.
    Scarpa J; Bruzelius E; Doupe P; Le M; Faghmous J; Baum A
    JAMA Netw Open; 2019 Mar; 2(3):e190005. PubMed ID: 30848803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Lowering Diastolic Pressure in Patients With and Without Cardiovascular Disease: Analysis of the SPRINT (Systolic Blood Pressure Intervention Trial).
    Khan NA; Rabkin SW; Zhao Y; McAlister FA; Park JE; Guan M; Chan S; Humphries KH
    Hypertension; 2018 May; 71(5):840-847. PubMed ID: 29581214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study.
    Okin PM; Kjeldsen SE; Devereux RB
    J Hypertens; 2018 Apr; 36(4):916-923. PubMed ID: 29176391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial.
    Plante TB; Juraschek SP; Zakai NA; Tracy RP; Cushman M
    Am J Cardiol; 2019 Dec; 124(11):1701-1706. PubMed ID: 31575423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
    Attar A; Sayadi M; Jannati M
    Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the SPRINT Trial on Hypertension Management.
    Ghazi L; Oparil S
    Annu Rev Med; 2018 Jan; 69():81-95. PubMed ID: 29414255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients.
    Aggarwal R; Petrie B; Bala W; Chiu N
    Hypertension; 2019 Jun; 73(6):1275-1282. PubMed ID: 31067189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generalizability of SPRINT Results to the U.S. Adult Population.
    Bress AP; Tanner RM; Hess R; Colantonio LD; Shimbo D; Muntner P
    J Am Coll Cardiol; 2016 Feb; 67(5):463-72. PubMed ID: 26562046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).
    Ambrosius WT; Sink KM; Foy CG; Berlowitz DR; Cheung AK; Cushman WC; Fine LJ; Goff DC; Johnson KC; Killeen AA; Lewis CE; Oparil S; Reboussin DM; Rocco MV; Snyder JK; Williamson JD; Wright JT; Whelton PK;
    Clin Trials; 2014 Oct; 11(5):532-46. PubMed ID: 24902920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial.
    Attar A; Nouri F; Borazjani R; Sayadi M
    PLoS One; 2020; 15(10):e0240102. PubMed ID: 33002071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension.
    Yano Y; Rakugi H; Bakris GL; Lloyd-Jones DM; Oparil S; Saruta T; Shimada K; Matsuoka H; Imai Y; Ogihara T
    Hypertension; 2017 Feb; 69(2):220-227. PubMed ID: 28049699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg.
    Tajeu GS; Booth JN; Colantonio LD; Gottesman RF; Howard G; Lackland DT; O'Brien EC; Oparil S; Ravenell J; Safford MM; Seals SR; Shimbo D; Shea S; Spruill TM; Tanner RM; Muntner P
    Circulation; 2017 Aug; 136(9):798-812. PubMed ID: 28634217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heart failure and the discrepancy between trials of intensive blood pressure management: an analysis of individual patient data.
    Aggarwal R; Mirzan H; Chiu N; Steinkamp J
    Clin Res Cardiol; 2018 Jul; 107(7):565-569. PubMed ID: 29480390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recruitment strategies and challenges in a large intervention trial: Systolic Blood Pressure Intervention Trial.
    Ramsey TM; Snyder JK; Lovato LC; Roumie CL; Glasser SP; Cosgrove NM; Olney CM; Tang RH; Johnson KC; Still CH; Gren LH; Childs JC; Crago OL; Summerson JH; Walsh SM; Perdue LH; Bankowski DM; Goff DC;
    Clin Trials; 2016 Jun; 13(3):319-30. PubMed ID: 26911833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants.
    Supiano MA; Lovato L; Ambrosius WT; Bates J; Beddhu S; Drawz P; Dwyer JP; Hamburg NM; Kitzman D; Lash J; Lustigova E; Miracle CM; Oparil S; Raj DS; Weiner DE; Taylor A; Vita JA; Yunis R; Chertow GM; Chonchol M
    PLoS One; 2018; 13(9):e0203305. PubMed ID: 30256784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morning Home Blood Pressure and Cardiovascular Events in Japanese Hypertensive Patients.
    Kario K; Iwashita M; Okuda Y; Sugiyama M; Saito I; Kushiro T; Teramukai S; Shimada K
    Hypertension; 2018 Oct; 72(4):854-861. PubMed ID: 30354719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline blood pressure control in Hispanics: characteristics of Hispanics in the Systolic Blood Pressure Intervention Trial.
    Rodriguez CJ; Still CH; Garcia KR; Wagenknecht L; White S; Bates JT; Del Cid MV; Lioudis M; Lopez Barrera N; Moreyra A; Punzi H; Ringer RJ; Cushman WC; Contreras G; Servilla K; Rocco M;
    J Clin Hypertens (Greenwich); 2017 Feb; 19(2):116-125. PubMed ID: 27862904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials.
    Beddhu S; Greene T; Boucher R; Cushman WC; Wei G; Stoddard G; Ix JH; Chonchol M; Kramer H; Cheung AK; Kimmel PL; Whelton PK; Chertow GM
    Lancet Diabetes Endocrinol; 2018 Jul; 6(7):555-563. PubMed ID: 29685860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.